[go: up one dir, main page]

NO931864D0 - Inhibering av celle - adhesjon protein - karbohydrat - reaksjoner - Google Patents

Inhibering av celle - adhesjon protein - karbohydrat - reaksjoner

Info

Publication number
NO931864D0
NO931864D0 NO931864A NO931864A NO931864D0 NO 931864 D0 NO931864 D0 NO 931864D0 NO 931864 A NO931864 A NO 931864A NO 931864 A NO931864 A NO 931864A NO 931864 D0 NO931864 D0 NO 931864D0
Authority
NO
Norway
Prior art keywords
carbohydrate
reactions
adhesion protein
cell inhibition
inhibition
Prior art date
Application number
NO931864A
Other languages
English (en)
Other versions
NO931864L (no
Inventor
Brian Seed
Gerd Walz
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of NO931864D0 publication Critical patent/NO931864D0/no
Publication of NO931864L publication Critical patent/NO931864L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO93931864A 1990-11-23 1993-05-21 Inhibering av celle - adhesjon protein - karbohydrat - reaksjoner NO931864L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61831490A 1990-11-23 1990-11-23
PCT/US1991/008605 WO1992009293A1 (en) 1990-11-23 1991-11-18 Inhibition of cell adhesion protein-carbohydrate interactions

Publications (2)

Publication Number Publication Date
NO931864D0 true NO931864D0 (no) 1993-05-21
NO931864L NO931864L (no) 1993-07-21

Family

ID=24477202

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931864A NO931864L (no) 1990-11-23 1993-05-21 Inhibering av celle - adhesjon protein - karbohydrat - reaksjoner

Country Status (16)

Country Link
US (5) US5858983A (no)
EP (1) EP0640129A1 (no)
JP (2) JPH06504619A (no)
AU (1) AU656934B2 (no)
BR (1) BR9106995A (no)
CA (1) CA2097617A1 (no)
CZ (1) CZ96893A3 (no)
FI (1) FI932336A7 (no)
HU (1) HUT64476A (no)
IE (1) IE914075A1 (no)
IL (1) IL100094A0 (no)
MC (1) MC2324A1 (no)
NO (1) NO931864L (no)
NZ (1) NZ240646A (no)
PT (1) PT99582A (no)
WO (1) WO1992009293A1 (no)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387884B1 (en) * 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) * 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
BR9106995A (pt) * 1990-11-23 1993-08-24 Gen Hospital Corp Inibicao de interacoes proteina-carboidrato com adesao celular
US5807745A (en) * 1991-03-11 1998-09-15 New England Medical Center Hospitals, Inc. Method of inhibiting PADGEM-mediated or ELAM-1-mediated leukocyte adhesion using an inhibitor comprising a Lex core component
US6121233A (en) * 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
EP0521692A3 (en) * 1991-07-02 1993-02-03 The Biomembrane Institute Inhibition of tumor cell metastasis potential and invasiveness by chemically-defined oligosaccharides, their derivatives, mimetics and antibodies directed to them
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
AU686116B2 (en) * 1992-10-02 1998-02-05 Alberta Research Council Inc. Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides
US5453272A (en) * 1992-10-02 1995-09-26 Alberta Research Council Lectin derived carbohydrate binding-peptide
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US7399847B1 (en) * 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
CA2331917A1 (en) * 1998-05-20 1999-11-25 Chugai Seiyaku Kabushiki Kaisha Novel method for gene cloning
ES2601882T5 (es) * 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2003025133A2 (en) * 2001-09-14 2003-03-27 Mimeon, Inc. Methods of making glycolmolecules with enhanced activities and uses thereof
US20030082188A1 (en) * 2001-10-11 2003-05-01 Tso J. Yun Treatment of prostate cancer by inhibitors of NCAM2
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
EP1534725A2 (en) 2002-05-16 2005-06-01 Glycomimetics, Inc. Compounds and methods for inhibiting selectin-mediated function
US20040096396A1 (en) * 2002-07-03 2004-05-20 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US20050287138A1 (en) * 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
US20060021071A1 (en) * 2003-10-09 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Cell in which genome is modified
CA2542121A1 (en) * 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Genomically modified cell neutralized to serum-free system
US7691810B2 (en) * 2003-10-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Method of producing recombinant antithrombin III composition
US20050187171A1 (en) * 2003-11-19 2005-08-25 Glycomimetics, Inc. Glycomimetic antagonists for both E-and P-selectins
EP1763533B1 (en) * 2003-11-19 2008-01-09 GlycoMimetics, Inc. Specific antagonist for both e- and p-selectins
US8201377B2 (en) * 2004-11-05 2012-06-19 Faus Group, Inc. Flooring system having multiple alignment points
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
WO2006127906A1 (en) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
WO2007021721A2 (en) * 2005-08-09 2007-02-22 Glycomimetics, Inc. Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas
SI2264043T1 (en) 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
WO2007055916A2 (en) * 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
WO2007112403A2 (en) * 2006-03-27 2007-10-04 The Regents Of The University Of Colorado Prevention and treatment of ischemia-reperfusion injury
EP3456351A1 (en) * 2006-04-05 2019-03-20 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
WO2008060378A2 (en) 2006-10-12 2008-05-22 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
NZ598863A (en) * 2007-02-09 2013-11-29 Glycomimetics Inc Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8895510B2 (en) * 2008-04-08 2014-11-25 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
JP2011517960A (ja) * 2008-04-22 2011-06-23 ザ ロックフェラー ユニバーシティー 抗炎症化合物の識別方法
US8518896B2 (en) * 2008-06-13 2013-08-27 Glycomimetics, Inc. Treatment of cancers of the blood using selected glycomimetic compounds
WO2010126888A1 (en) * 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
CN101921336B (zh) * 2009-06-11 2013-02-27 北京华大蛋白质研发中心有限公司 一种抗人α1酸性糖蛋白的单克隆抗体及其制备方法
EP2556163B1 (en) 2010-04-07 2016-08-10 Momenta Pharmaceuticals, Inc. Method for quantifying high mannose containing glycoforms
US9187552B2 (en) 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
CN103782168B (zh) 2011-03-12 2016-03-16 动量制药公司 在糖蛋白产品中包含n-乙酰己糖胺的n-聚醣
JP2014517846A (ja) 2011-05-25 2014-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 改善された特性を有するＦｃ含有ポリペプチドの製造方法
SI2794626T1 (en) 2011-12-22 2018-02-28 Glycomimetics, Inc. E-SELECTINE ANTAGONIST COMPOUNDS
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
SI2928476T1 (en) 2012-12-07 2018-06-29 Glycomimetics, Inc. COMPONENTS, INSTALLATIONS AND PROCEDURES OF THE APPLICATION OF E-SELECTINE OF ANTAGONISTS FOR THE MOBILIZATION OF HEMATOPOETIC CELLS
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
DK3227310T3 (da) 2014-12-03 2019-09-30 Glycomimetics Inc Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CN117298287A (zh) 2016-10-07 2023-12-29 糖模拟物有限公司 高效的多聚体e-选择蛋白拮抗剂
JP7272956B2 (ja) 2017-03-15 2023-05-12 グリコミメティクス， インコーポレイテッド Ｅ－セレクチンアンタゴニストとしてのガラクトピラノシル－シクロヘキシル誘導体
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
KR20200104889A (ko) 2017-12-29 2020-09-04 글리코미메틱스, 인크. E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
CN111867601A (zh) 2018-03-05 2020-10-30 糖模拟物有限公司 用于治疗急性髓系白血病及相关病症的方法
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
MX2022009130A (es) 2020-01-24 2022-08-22 Pfizer Anticuerpos anti-e-selectina, composiciones y metodos de uso.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4184917A (en) * 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
DE2621908A1 (de) * 1975-05-26 1976-12-09 Sandoz Ag Neues diagnostikum fuer maligne tumore
JPS53136586A (en) * 1977-05-02 1978-11-29 Ajinomoto Co Inc Preparation of llglutamic acidd*c* semialdehyde
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS60123494A (ja) * 1983-12-08 1985-07-02 Rikagaku Kenkyusho シアル酸含有オリゴ糖およびその製造法
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
JPS6283898A (ja) * 1985-10-09 1987-04-17 Kyowa Hakko Kogyo Co Ltd 抗ヒト肺腺癌特異的単クロ−ン性抗体
US4851511A (en) * 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS63152393A (ja) * 1986-07-03 1988-06-24 Takeda Chem Ind Ltd グリコシル誘導体
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
ES2064327T3 (es) * 1987-11-02 1995-02-01 Baylor College Medicine Uso de icam-1 o de sus derivados funcionales para el tratamiento de una inflamacion no especifica.
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
EP0323802A3 (en) * 1987-12-24 1989-07-26 Sandoz Ag Monoclonal antibodies against, and cell surface antigen of, lung carcinoma
JP2849683B2 (ja) * 1988-03-11 1999-01-20 オオツカ アメリカ ファーマシューティカル、インコーポレーティッド 「動物及びヒトのムチンを用い、並びに合成炭水化物−担体結合物を用いた免疫による、ヒト癌関連抗原に対するモノクローナル抗体」
EP0534944B1 (en) * 1988-11-14 1996-09-11 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
FR2654876B1 (fr) * 1989-11-23 1993-11-12 Commissariat A Energie Atomique Dispositif de charge de moyens d'accumulation d'energie electrique, muni de moyens permettant de maitriser cette charge.
WO1991016900A1 (en) * 1990-04-27 1991-11-14 Biogen, Inc. Fucosyl transferases involved in adhesion molecule expression
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5143712A (en) * 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5211936A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a cite of inflammation utilizing elam-1 ligands site
BR9106995A (pt) * 1990-11-23 1993-08-24 Gen Hospital Corp Inibicao de interacoes proteina-carboidrato com adesao celular
CA2108786A1 (en) * 1991-04-19 1992-10-20 John L. Magnani Compositions and methods for endothelial binding
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates

Also Published As

Publication number Publication date
IE914075A1 (en) 1992-06-03
US6156881A (en) 2000-12-05
FI932336A0 (fi) 1993-05-21
JP2000325092A (ja) 2000-11-28
NO931864L (no) 1993-07-21
US5858983A (en) 1999-01-12
US6613746B1 (en) 2003-09-02
IL100094A0 (en) 1992-08-18
HUT64476A (en) 1994-01-28
PT99582A (pt) 1992-10-30
US5723583A (en) 1998-03-03
WO1992009293A1 (en) 1992-06-11
US5801044A (en) 1998-09-01
MC2324A1 (fr) 1994-01-18
FI932336L (fi) 1993-05-21
AU9061891A (en) 1992-06-25
AU656934B2 (en) 1995-02-23
HU9301510D0 (en) 1993-10-28
FI932336A7 (fi) 1993-05-21
NZ240646A (en) 1994-01-26
CA2097617A1 (en) 1992-05-23
EP0640129A4 (en) 1994-07-05
JPH06504619A (ja) 1994-05-26
CZ96893A3 (en) 1993-12-15
EP0640129A1 (en) 1995-03-01
BR9106995A (pt) 1993-08-24

Similar Documents

Publication Publication Date Title
NO931864D0 (no) Inhibering av celle - adhesjon protein - karbohydrat - reaksjoner
FI931357A0 (fi) Framstaellning av polyhydroxifettsyraamider i naervaro av loesningsmedel
FI932024L (fi) Foerfarande foer aostadkommande av kontrollerade utskiljningsprofiler i kieselskivor
FI930848A0 (fi) Foerfarande foer separering av ilmenit
FI923931L (fi) Anordning foer granskning av insidan av en foergrenad roerlinje
FI930509L (fi) Anvaendning av graensytpolymeriserade membraner i doseringsanordningar
FI930165A0 (fi) Framstaellning av synnerligen aktiva tvaettmedelspartiklar
FI925884A7 (fi) Avlaegsning av signaldistorsion
FI924569L (fi) Foerfarande foer enantioselektiv framstaellning av fenylisoserinderivat
FI924568L (fi) Foerfarande foer stereoselektiv framstaellning av fenylisoserinderivat
FI925988L (fi) Foerfarande foer framstaellning av b-laktamer
FI925515L (fi) Foerfarande foer framstaellning av alfa-2-interferonkristaller
FI925415L (fi) Framstaellning av substituerade piperidiner
FI925435A7 (fi) Foerfarande foer beredning av en vattenloesning av natriumfoereningar
FI924512L (fi) Foerfarande foer synkronisering av en pseudoslumpmaessig binaersekvens i en desscrambler
FI924436A7 (fi) Foerfarande foer tillverkning av expanderade polystyrenfolier
FI930551A7 (fi) Paristoja
FI932552L (fi) Foerfarande foer framstaellning av en fast enhet doseringsform foer reglerad utloesningen
FI925805L (fi) Framstaellning av kompositmaterial
FI931552L (fi) Cell foer maetning av el-ledningsfoermaoga
FI924826L (fi) Fettkompositioner innehaollande polyestrar av polyolfettsyror
FI925609A0 (fi) Foerfarande foer framstaellning av sykliska sulfater
FI923779L (fi) Foerbaettringar i tillverkningen av nylongarn
FI923776A7 (fi) Foerfarande foer formning av pappersark
FI924374L (fi) Foerfarande foer dubbelsidig belaeggning av en roerlig materialbana